193 results on '"Pavel, Marianne E."'
Search Results
2. 177Lu-Dotatate plus long-acting octreotide versus high‑dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial
3. Matching-adjusted indirect treatment comparison of [177Lu]Lu-DOTA-TATE, everolimus and sunitinib in advanced, unresectable gastroenteropancreatic neuroendocrine tumours: Relative effectiveness of [177Lu]Lu-DOTA-TATE in gastroenteropancreatic neuroendocrine tumours
4. Surgery with Radical Intent: Is There an Indication for G3 Neuroendocrine Neoplasms?
5. Biochemical Responses in Symptomatic and Asymptomatic Patients with Neuroendocrine Tumors: Pooled Analysis of Two Phase 3 Trials
6. Tumor growth rate as a metric of progression, response, and prognosis in pancreatic and intestinal neuroendocrine tumors
7. Efficacy and Toxicity of 5-Fluorouracil–Oxaliplatin in Gastroenteropancreatic Neuroendocrine Neoplasms
8. Prognostic value of the neutrophil/lymphocyte ratio in enteropancreatic neuroendocrine tumors
9. Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study
10. High rate of Ki‐67 increase in entero‐pancreatic NET relapses after surgery with curative intent
11. Gastroduodenal neuroendocrine neoplasms including gastrinoma — update of the diagnostic and therapeutic guidelines (recommended by the Polish Network of Neuroendocrine Tumours) [Nowotwory neuroendokrynne żołądka i dwunastnicy z uwzględnieniem gastrinoma — uaktualnione zasady postępowania (rekomendowane przez Polską Sieć Guzów Neuroendokrynnych)]
12. Colorectal neuroendocrine neoplasms — update of the diagnostic and therapeutic guidelines (recommended by the Polish Network of Neuroendocrine Tumours) [Nowotwory neuroendokrynne jelita grubego — uaktualnione zasady diagnostyki i leczenia (rekomendowane przez Polską Sieć Guzów Neuroendokrynych)]
13. Neuroendocrine neoplasms of the small intestine and the appendix — update of the diagnostic and therapeutic guidelines (recommended by the Polish Network of Neuroendocrine Tumours) [Nowotwory neuroendokrynne jelita cienkiego i wyrostka robaczkowego — uaktualnione zasady diagnostyki i leczenia (rekomendowane przez Polską Sieć Guzów Neuroendokrynnych)]
14. Update of the diagnostic and therapeutic guidelines for gastro-entero-pancreatic neuroendocrine neoplasms (recommended by the Polish Network of Neuroendocrine Tumours) [Aktualizacja zaleceń ogólnych dotyczących postępowania diagnostyczno-terapeutycznego w nowotworach neuroendokrynnych układu pokarmowego (rekomendowane przez Polską Sieć Guzów Neuroendokrynnych)]
15. Pancreatic neuroendocrine neoplasms — update of the diagnostic and therapeutic guidelines (recommended by the Polish Network of Neuroendocrine Tumours) [Nowotwory neuroendokrynne trzustki — uaktualnione zasady diagnostyki i leczenia (rekomendowane przez Polską Sieć Guzów Neuroendokrynych)]
16. Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study
17. Survey of challenges in access to diagnostics and treatment for neuroendocrine tumor patients (SCAN): The diagnostic process of GEP-NETs in Australia, Canada, China, France, Germany, the United Kingdom, and the United States of America.
18. A giant neuroendocrine tumor of the thymus gland causing superior vena cava syndrome
19. Treatment outcomes of advanced digestive well-differentiated grade 3 NETs
20. Matching-adjusted indirect treatment comparison of [177Lu]Lu-DOTA-TATE, everolimus and sunitinib in advanced, unresectable gastroenteropancreatic neuroendocrine tumours:Relative effectiveness of [177Lu]Lu-DOTA-TATE in gastroenteropancreatic neuroendocrine tumours
21. Cardiac surgery for carcinoid heart disease in 12 cases
22. Treatments and ongoing monitoring for patients with neuroendocrine tumors, monitored by medical oncologists: Scan comparative data between advanced economies (AE) and emerging and developing economies (EDE).
23. Relationship between metabolic toxicity and efficacy of everolimus in patients with neuroendocrine tumors: A pooled analysis from the randomized, phase 3 RADIANT‐3 and RADIANT‐4 trials
24. Spartalizumab in metastatic, well/poorly differentiated neuroendocrine neoplasms
25. Doxorubicin and streptozotocin after failed biotherapy of neuroendocrine tumors
26. Practical Management of Everolimus-Related Toxicities in Patients with Advanced Solid Tumors
27. Distinct Cut-Off Values of Ki-67-Index for NET-Grading Predict Long-Term Outcome in Gastrointestinal Neuroendocrine (Carcinoid) Neoplasms
28. Everolimus for Advanced Pancreatic Neuroendocrine Tumors
29. Radical intended surgery for highly selected stage IV neuroendocrine neoplasms G3
30. Unmet medical needs in metastatic lung and digestive neuroendocrine neoplasms
31. Unmet Medical Needs in Metastatic Lung and Digestive Neuroendocrine Neoplasms
32. Circulating levels of angiogenic cytokines can predict tumour progression and prognosis in neuroendocrine carcinomas
33. Surgery with Radical Intent: Is There an Indication for G3 Neuroendocrine Neoplasms?
34. Health-related quality of life in patients with advanced, nonfunctional, well-differentiated gastrointestinal or lung neuroendocrine tumors with everolimus vs. placebo in the phase 3, randomized, RADIANT-4 trial
35. Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study
36. Health-related quality of life for everolimus versus placebo in patients with advanced, non-functional, well-differentiated gastrointestinal or lung neuroendocrine tumours (RADIANT-4): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
37. Everolimus Effect on Gastrin and Glucagon in Pancreatic Neuroendocrine Tumors
38. Safety and tolerability of lanreotide autogel/depot (LAN) in patients (pts) with neuroendocrine tumors (NETs): Pooled analysis of clinical studies.
39. Evaluation of meaningful change in bowel move frequency for patients with carcinoid syndrome.
40. Health-related quality of life (HRQoL) in patients with advanced neuroendocrine tumors (NET) of gastrointestinal origin in the phase 3 RADIANT-4 trial.
41. Functional Imaging in the Follow-Up of Enteropancreatic Neuroendocrine Tumors: Clinical Usefulness and Indications
42. Effect of Lanreotide Depot/Autogel on Urinary 5‐Hydroxyindoleacetic Acid and Plasma Chromogranin A Biomarkers in Nonfunctional Metastatic Enteropancreatic Neuroendocrine Tumors.
43. WOMEN IN CANCER PROFILE: Neuroendocrine tumors: moving from the land of small tumors to an expanding universe
44. WOMEN IN CANCER THEMATIC REVIEW: Systemic therapies in neuroendocrine tumors and novel approaches toward personalized medicine
45. Health-related quality of life (HRQoL) in patients with advanced, nonfunctional, well-differentiated gastrointestinal (GI) or lung neuroendocrine tumors (NET) in the phase 3 RADIANT-4 trial.
46. Association of disease progression, health-related quality of life (HRQoL), and utility in patients (pts) with advanced, nonfunctional, well-differentiated gastrointestinal (GI) or lung neuroendocrine tumors (NET) in the phase 3 RADIANT-4 trial.
47. REMINET: A European, multicentre, PHASE II/III randomized double-blind, placebo-controlled study evaluating lanreotide as maintenance therapy after first-line treatment in patients with non-resectable duodeno-pancreatic neuroendocrine tumours.
48. Exploratory analysis of tumor growth rate (TGR) with lanreotide depot/autogel (LAN) in patients (pts) with neuroendocrine tumors (NETs) from the CLARINET study.
49. External validation of a prognostic score in patients (pts) with high-grade gastrointestinal neuroendocrine carcinomas (GI-NECs).
50. Curative resection in digestive neuroendocrine neoplasms: Recurrence-free survival rate and definition of a risk score for recurrence.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.